sodium;(4E)-4-[(1-hydroxynaphthalen-2-yl)hydrazinylidene]-7-nitro-3-oxonaphthalene-1-sulfonate

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: sodium;(4E)-4-[(1-hydroxynaphthalen-2-yl)hydrazinylidene]-7-nitro-3-oxonaphthalene-1-sulfonate
• 化学式: C20H12N3NaO7S
• 分子量: 461.4
• InChiKey: JHUJLRKQZAPSDP-KWNKHXGFSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -0.26
• 重原子数：
  32
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  173
• 氢给体数：
  2
• 氢受体数：
  9

文献信息

• [EN] SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE<br/>[FR] DÉRIVÉS AMINÉS À SUBSTITUTION ARYLE ET PROCÉDÉS D'UTILISATION
  申请人：AMGEN INC

  公开号：WO2006012374A1

  公开（公告）日：2006-02-02

  The present invention provides classes of compounds, including-their pharmaceutically acceptable derivatives, useful for treating angiogenesis and related diseases such as cancer. Formula I and II wherein R is a 9- or 10-membered heterocyclyl ring selected from 7-isoquinolinyl,..2-methyl-3-oxo-2,3-dihydroindazol-6-yl, [1,6]-naphthydrin-3-yl, [1,7]-naphthydrin-2-yl, 1-oxo-2,3-dihydrobenzofuran-4-yl, 3-oxo-2,3-dihydrobenzofuran-5-yl, dihydro-benzodioxinyl, 6-quinazolinyl, 2-amino-6-quinazolinyl, 4-methylamino-6-quinazolinyl, 2,4-diamino-6 quinazolinyl, 3-oxo-3,4-dihydro-1,4-benzoxazin-6-yl, 2,2-difluoro-l;3-benzodioxol-5-yl and 2,2,3,3 tetrafluoro-2,3-dihydro-l,4-benzodioxin-6-yl, each of which is optionally substituted with one or more substituents selected from halo, haloakyl, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, N-dimethylamino-C1-6-alkyl, N-dimethylamino-C1-6-alkoxy, amino, alkyl-carbonylamino, morpholino-sulfonyl, amino-sulfonyl, oxazolyl, pyrrolyl,4 morpholinyl, carboxyl, cyano, and acetyl; wherein R1 in formula I is selected from unsubstituted or substituted phenyl, 5-6 membered heteroaryl, 9-10 membered bicyclic heterocyclyl and 11-14 membered tricyclic heterocyclyl, and R1 in formula II is selected from specific bicyclic heterocycles.

  本发明提供了一类化合物，包括其药用可接受的衍生物，用于治疗血管生成和相关疾病，如癌症。其中R为从7-异喹啉基、2-甲基-3-氧代-2,3-二氢吲哚-6-基、[1,6]-萘啶-3-基、[1,7]-萘啶-2-基、1-氧代-2,3-二氢苯并呋喃-4-基、3-氧代-2,3-二氢苯并呋喃-5-基、二氢苯并二氧杂环基、6-喹唑啉基、2-氨基-6-喹唑啉基、4-甲氨基-6-喹唑啉基、2,4-二氨基-6-喹唑啉基、3-氧代-3,4-二氢-1,4-苯并噁嗪-6-基、2,2-二氟-1,3-苯并二氧杂环-5-基和2,2,3,3-四氟-2,3-二氢-1,4-苯并二氧杂环-6-基中选择的9-或10-成员杂环基，其中每个基可选择地被一个或多个来自卤素、卤代烷基、C1-6烷基、C2-8烯基、C2-8炔基、N-二甲氨基-C1-6-烷基、N-二甲氨基-C1-6-烷氧基、氨基、烷基-羰基氨基、吗啉磺酰基、氨基磺酰基、噁唑基、吡咯基、吗啉基、羧基、氰基和乙酰基的取代基取代；其中式I中的R1从未取代或取代的苯基、5-6成员杂芳基、9-10成员双环杂环基和11-14成员三环杂环基中选择，式II中的R1从特定的双环杂环基中选择。
• Aromatic ethers and process for producing aromatic ethers
  申请人：——

  公开号：US20040181099A1

  公开（公告）日：2004-09-16

  According to a production process, aromatic ethers are producible by reacting phenols with an oxirane compound with use of an anion exchange resin as a catalyst. According to another production process, aromatic ethers having an alcoholic hydroxyl group are producible by a crystallization-purification step of using a solvent having a solubility parameter ranging from 7.5 to 12.5 for purification by crystallization. Further, according to still another production process, producible are aromatic ethers having an alcoholic hydroxyl group, wherein the content of a metal in the aromatic ethers is less than 100 ppm by mass, and the content of a halogen element in the aromatic ethers is less than 100 ppm by mass.

  根据一个生产过程，芳香醚可通过将酚与环氧化合物反应，并使用阴离子交换树脂作为催化剂来生产。根据另一个生产过程，具有醇羟基的芳香醚可通过结晶纯化步骤，使用溶剂进行结晶纯化，其溶解度参数范围为7.5至12.5进行生产。此外，根据另一个生产过程，可生产具有醇羟基的芳香醚，其中芳香醚中金属的含量小于100ppm，卤素元素的含量小于100ppm。
• [EN] 1, 2, 3-TRIAZOLE CONTAINING PROTEIN KINASE SENSORS<br/>[FR] 1, 2, 3-TRIAZOLE CONTENANT DES DÉTECTEURS DE PROTÉINE KINASE
  申请人：MASSACHUSETTS INST TECHNOLOGY

  公开号：WO2011025546A1

  公开（公告）日：2011-03-03

  The present invention generally relates to compositions and methods for determining kinase activity. In some cases, the compositions comprise a triazole heterocycle. In some embodiments, the compositions comprise a quinoline moiety. In one aspect, the present invention is directed to compositions that undergo chelation- enhanced fluorescence (CHEF). In some cases, the compositions may have fluorescence emission spectra with peak maxima greater than 490 nm. The compositions of the present invention can be used, in certain embodiments, to detect phosphorylated substrates and biological processes such as phosphorylation events.

  本发明通常涉及用于确定激酶活性的组合物和方法。在某些情况下，这些组合物包括三唑杂环。在某些实施例中，这些组合物包括喹啉基团。在一个方面，本发明涉及能够经历螯合增强荧光（CHEF）的组合物。在某些情况下，这些组合物可能具有峰值大于490纳米的荧光发射光谱。在某些实施例中，本发明的组合物可用于检测磷酸化底物和生物过程，如磷酸化事件。
• KINASE SENSORS
  申请人：IMPERIALI BARBARA

  公开号：US20110053180A1

  公开（公告）日：2011-03-03

  The present invention generally relates to compositions and methods for determining kinase activity. In some cases, the compositions comprise a triazole heterocycle. In some embodiments, the compositions comprise a quinoline moiety. In one aspect, the present invention is directed to compositions that undergo chelation-enhanced fluorescence (CHEF). In some cases, the compositions may have fluorescence emission spectra with peak maxima greater than 490 nm. The compositions of the present invention can be used, in certain embodiments, to detect phosphorylated substrates and biological processes such as phosphorylation events.

  本发明通常涉及用于确定激酶活性的组合物和方法。在某些情况下，该组合物包括三唑杂环。在某些实施例中，该组合物包括喹啉基团。在一方面，本发明涉及经过螯合增强荧光（CHEF）的组合物。在某些情况下，该组合物可能具有荧光发射光谱，其峰值最大值大于490纳米。在某些实施例中，本发明的组合物可用于检测磷酸化底物和生物过程，例如磷酸化事件。
• Methods for the preparation and formulation of magnesium valproate hydrate
  申请人：Nelson Jean Deanna

  公开号：US20070083063A1

  公开（公告）日：2007-04-12

  The present invention relates to methods for preparing magnesium valproate hydrate and administering this compound to a subject in need of treatment with valproate. Pharmaceutical compositions are also provided that are useful therapies for the treatment of neurological, immunological, and viral-mediated disorders in warm-blooded mammals.

  本发明涉及制备水合硬脂酸镁的方法，并将该化合物用于需要使用硬脂酸镁治疗的受试者。同时，本发明还提供了制药组合物，可用于治疗温血动物的神经、免疫和病毒介导的疾病。